606 related articles for article (PubMed ID: 32879113)
1. Antiviral therapy for coronavirus disease 2019.
Gong S; Su J; Yan X; Li F; Hu L; Liu S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2020 May; 45(5):598-602. PubMed ID: 32879113
[TBL] [Abstract][Full Text] [Related]
2. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
3. [Potential antiviral therapeutics for 2019 Novel Coronavirus].
Li H; Wang YM; Xu JY; Cao B
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Mar; 43(3):170-172. PubMed ID: 32164080
[TBL] [Abstract][Full Text] [Related]
4. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
[TBL] [Abstract][Full Text] [Related]
5. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
7. A global treatments for coronaviruses including COVID-19.
Yousefi B; Valizadeh S; Ghaffari H; Vahedi A; Karbalaei M; Eslami M
J Cell Physiol; 2020 Dec; 235(12):9133-9142. PubMed ID: 32394467
[TBL] [Abstract][Full Text] [Related]
8. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) - an update on the status.
Abd El-Aziz TM; Stockand JD
Infect Genet Evol; 2020 Sep; 83():104327. PubMed ID: 32320825
[TBL] [Abstract][Full Text] [Related]
9. Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.
Park SJ; Yu KM; Kim YI; Kim SM; Kim EH; Kim SG; Kim EJ; Casel MAB; Rollon R; Jang SG; Lee MH; Chang JH; Song MS; Jeong HW; Choi Y; Chen W; Shin WJ; Jung JU; Choi YK
mBio; 2020 May; 11(3):. PubMed ID: 32444382
[TBL] [Abstract][Full Text] [Related]
10. Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: Protocol for restricted public health emergency use.
Bhatnagar T; Murhekar MV; Soneja M; Gupta N; Giri S; Wig N; Gangakhedkar R
Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):184-189. PubMed ID: 32362644
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
[TBL] [Abstract][Full Text] [Related]
12. [Potential therapeutic drugs for novel coronavirus pneumonia].
Nie NF; He Y
Zhonghua Jie He He Hu Xi Za Zhi; 2020 Nov; 43(11):970-974. PubMed ID: 33137863
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of current therapeutic options for COVID-19 - lessons to be learnt from SARS and MERS epidemic: A systematic review and meta-analysis.
Zhong H; Wang Y; Zhang ZL; Liu YX; Le KJ; Cui M; Yu YT; Gu ZC; Gao Y; Lin HW
Pharmacol Res; 2020 Jul; 157():104872. PubMed ID: 32360583
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
Song Y; Zhang M; Yin L; Wang K; Zhou Y; Zhou M; Lu Y
Int J Antimicrob Agents; 2020 Aug; 56(2):106080. PubMed ID: 32634603
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
Martinez MA
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
[TBL] [Abstract][Full Text] [Related]
17. Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.
Khan Z; Karataş Y; Rahman H
Adv Ther; 2020 Jun; 37(6):2575-2579. PubMed ID: 32350686
[TBL] [Abstract][Full Text] [Related]
18. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Miao H; Li H; Yao Y; Wu M; Lu C; Wang J; Tian M; Li Y; Luo P; Gu J; Yuan B; Wang S; Zhao X; Gan W; Zhao D
Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2211-2223. PubMed ID: 32761481
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]